文献速递类风湿关节炎

治疗前肠道微生物组与新发类风湿关节炎甲氨蝶呤无应答相关

The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2021-05-02

该研究对新发未用药类风湿关节炎患者基线肠道微生物组进行16S rRNA基因和鸟枪法宏基因组测序(n=26),并在独立队列(n=21)中验证。研究发现肠道细菌分类群及其基因丰度与未来临床应答显著相关,基于微生物组的机器学习模型可预测甲氨蝶呤无应答,且体外孵育后甲氨蝶呤剩余水平与未来临床应答幅度相关。

要点

  • 基线肠道微生物组特征与甲氨蝶呤临床应答显著相关。
  • 基于宏基因组数据的模型可预测独立队列中甲氨蝶呤无应答。
  • 肠道微生物组可能直接影响甲氨蝶呤代谢与治疗结局。

核心结论

  • 治疗前肠道微生物组与新发类风湿关节炎患者口服甲氨蝶呤无应答相关,支持其作为预后工具和潜在治疗靶点的价值。

研究设计与样本

  • 对26例未用药新发类风湿关节炎患者基线肠道微生物组行16S rRNA基因和鸟枪法宏基因组测序,并在21例独立队列中验证。
  • 开展离体实验结合代谢组学分析,评估微生物组驱动的甲氨蝶呤消耗与临床应答的关联。

主要发现

  • 肠道细菌分类群及其基因丰度与未来临床应答显著相关(q < 0.05),包括与嘌呤和甲氨蝶呤代谢相关的直系同源基因。
  • 基于宏基因组数据的机器学习模型在独立患者组中预测甲氨蝶呤无应答。
  • 治疗前远端肠道样本离体孵育后甲氨蝶呤剩余水平与未来临床应答幅度显著相关。

临床怎么用

  • 治疗前肠道微生物组特征可能辅助预测新发类风湿关节炎患者口服甲氨蝶呤是否应答。
  • 肠道微生物组可作为类风湿关节炎治疗的潜在干预靶点。

局限性

  • 样本量较小(发现队列26例,验证队列21例),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although oral methotrexate (MTX) remains the anchor drug for rheumatoid arthritis (RA), up to 50% of patients do not achieve a clinically adequate outcome. In addition, there is a lack of prognostic tools for treatment response prior to drug initiation. This study was undertaken to investigate whether interindividual differences in the human gut microbiome can aid in the prediction of MTX efficacy in new-onset RA. METHODS: We performed 16S ribosomal RNA gene and shotgun metagenomic sequencing on the baseline gut microbiomes of drug-naive patients with new-onset RA (n = 26). Results were validated in an additional independent cohort (n = 21). To gain insight into potential microbial mechanisms, we conducted ex vivo experiments coupled with metabolomics analysis to evaluate the association between microbiome-driven MTX depletion and clinical response. RESULTS: Our analysis revealed significant associations of the abundance of gut bacterial taxa and their genes with future clinical response (q < 0.05), including orthologs related to purine and MTX metabolism. Machine learning techniques were applied to the metagenomic data, resulting in a microbiome-based model that predicted lack of response to MTX in an independent group of patients. Finally, MTX levels remaining after ex vivo incubation with distal gut samples from pretreatment RA patients significantly correlated with the magnitude of future clinical response, suggesting a possible direct effect of the gut microbiome on MTX metabolism and treatment outcomes. CONCLUSION: Taken together, these findings are the first step toward predicting lack of response to oral MTX in patients with new-onset RA and support the value of the gut microbiome as a possible prognostic tool and as a potential target in RA therapeutics.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Artacho A, Isaac S, Nayak R, et al. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. Arthritis Rheumatol. 2021. PMID: 33314800. doi:10.1002/art.41622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。